Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole brain radiotherapy with concomitant eribulin for breast cancer brain metastases
jRCT1031250065Recruiting
- Sponsor
- University of Tsukuba Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of eribulin in breast cancer, sponsored by University of Tsukuba Hospital. Primary endpoint: Dose-limiting toxicities (DLTs). Started Nov 2025; status: recruiting.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1031250065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250065.